What do you monitor?
Curated feeds for your role. Pick your area and get exactly the sources you need.
Compliance & Legal
Legal Research
Court opinions, regulatory guidance, and enforcement actions. AI-summarized.
Financial Compliance
SEC, OCC, FDIC, Fed, FINRA, CFPB, FASB, and state banking regulators. One feed.
Insurance Compliance
State commissioner bulletins, NAIC model laws, and DOI enforcement actions.
Environmental Compliance
EPA enforcement, state environmental agencies, PFAS regulatory updates.
Data Privacy
State AG privacy enforcement, FTC actions, CPPA rulemaking, and HIPAA enforcement.
Tax Compliance
IRS guidance changes and state tax department bulletins.
AML Compliance
FinCEN, OCC, FDIC, Fed, FATF, and banking regulator enforcement.
Labor & Employment
NLRB decisions, EEOC guidance, DOL wage updates, and 50-state labor law changes.
Immigration Law
USCIS policy changes, visa bulletin updates, CBP processing changes.
Industry
Pharma & Life Sciences
FDA warning letters, drug approvals, ICH guidelines, EMA updates, and DEA scheduling.
Energy & Utilities
FERC orders, state PUC decisions, and energy regulatory changes.
Cybersecurity
CISA KEV catalog, ICS-CERT, NSA advisories, NIST CSF, and FedRAMP updates.
Healthcare Compliance
CMS transmittals, OIG work plan, HIPAA enforcement, and Medicaid updates.
Trade & Procurement
Recent changes
Mayo Clinic methotrexate monitoring trial, rheumatic diseases
The National Library of Medicine registered a new clinical trial (NCT07512401) on ClinicalTrials.gov. The study, sponsored by Mayo Clinic, will investigate methotrexate monitoring practices in patients with rheumatic diseases. The trial is currently recruiting participants at Mayo Clinic locations in Arizona and Minnesota.
CAR-NK Cell Therapy Trial for HER2+ Breast Cancer
ClinicalTrials.gov registered a Phase I/II clinical trial (NCT07510802) evaluating CAR-NK cell therapy for HER2+ breast cancer. The trial is sponsored by a Beijing-based biotechnology company. This registry entry provides public disclosure of ongoing research but does not establish new regulatory obligations.
Zhejiang University Thiotepa trial for meningeal-risk Glioblastoma
The National Library of Medicine registered clinical trial NCT07511725 on ClinicalTrials.gov. The trial, sponsored by Zhejiang University, evaluates Thiotepa treatment for meningeal-risk Glioblastoma. ClinicalTrials.gov serves as a public registry for clinical research studies meeting registration requirements under FDAAA 801.
Oxford wearable tech study, transfusion patients, blood cancers
The National Library of Medicine registered a new clinical study (NCT07511829) on ClinicalTrials.gov conducted by Oxford University. The study will evaluate wearable technology in patients with blood cancers who require transfusions. Registration fulfills federal requirements for clinical trial reporting.
OPKO Health OPK-88006 Phase 1/2 Clinical Trial Registration
ClinicalTrials.gov registered a Phase 1/2 clinical trial (NCT07512427) sponsored by OPKO Health evaluating OPK-88006. The study registration provides standard protocol details including eligibility criteria, study design, and investigator information. ClinicalTrials.gov is maintained by the National Library of Medicine under NIH.
Brain Stimulation for Mild Cognitive Impairment
The National Library of Medicine registered a new clinical trial (NCT07512193) on ClinicalTrials.gov. The study, sponsored by Johns Hopkins University, will evaluate brain stimulation as an intervention for mild cognitive impairment.
FTC Monetary Remedies and Data-Driven Economy Podcast Discussion
The ABA Antitrust Law Section published a podcast discussion featuring former FTC economists and staff examining monetary remedies available to the FTC in data-driven economy enforcement actions. The panel analyzes how the FTC calculates and structures monetary relief in cases involving digital markets, privacy violations, and deceptive practices.
Credit agency wins FCRA case, no actionable harm
Credit agency wins FCRA case, no actionable harm
Credit Agreement Implications of Supreme Court Tariff Decision
Orrick, Herrington & Sutcliffe LLP analyzes credit agreement implications following the Supreme Court's February 20, 2026 ruling invalidating IEEPA tariffs. The analysis addresses accounting treatment of potential refunds under FASB ASC 410-30 and ASC 450, and covers impacts on interest margins, financial covenants, incurrence tests, and extraordinary receipts provisions. Borrowers with existing credit facilities should evaluate these developments with their accountants and lenders.
When Participant Growth Becomes a Fiduciary Prompt — Not a Punchline
The Rosenbaum Law Firm published an analysis warning retirement plan sponsors that participant growth metrics do not equate to fiduciary compliance. The article uses Empower's reported addition of 500,000 net new retirement plan participants as context to highlight that larger participant populations increase operational complexity, testing nuances, and probability of service breakdowns.
Browse by country
United States
1815 sources
United Kingdom
90 sources
European Union
77 sources
Canada
39 sources
International
39 sources
Australia
22 sources
Singapore
21 sources
India
13 sources
France
13 sources
Japan
10 sources
Italy
8 sources
Hong Kong
7 sources
Switzerland
6 sources
Ireland
6 sources
Germany
6 sources
Poland
5 sources
MT
5 sources
UAE
4 sources
New Zealand
4 sources
Luxembourg
4 sources
South Africa
3 sources
NG
3 sources
South Korea
3 sources
GH
3 sources
CL
2 sources
GG
2 sources
GI
2 sources
SA
2 sources
Austria
2 sources
KY
2 sources
CY
2 sources
KE
2 sources
Norway
2 sources
Netherlands
2 sources
IL
1 sources
Greece
1 sources
INT
1 sources
LK
1 sources
SE
1 sources
Hungary
1 sources
Romania
1 sources
Uganda
1 sources
Spain
1 sources
Croatia
1 sources
CO
1 sources
Finland
1 sources
BM
1 sources
MU
1 sources
QA
1 sources
DK
1 sources
Browse by category
Courts & Legal
362 sources
Banking & Finance
292 sources
Government & Legislation
280 sources
Trade & Sanctions
136 sources
Healthcare
136 sources
Labor & Employment
113 sources
Securities & Markets
104 sources
Pharma & Drug Safety
104 sources
Energy
101 sources
Environment
86 sources
Data Privacy & Cybersecurity
74 sources
Tax
66 sources
Agriculture & Food Safety
64 sources
Insurance
58 sources
Transportation
57 sources
Defense & National Security
52 sources
Telecom & Technology
47 sources
Consumer Protection
44 sources
Education
19 sources
Housing
16 sources
Securities Regulation
9 sources
Environmental Regulation
8 sources
Immigration
8 sources
Public Health
3 sources
AI Regulation
3 sources
Financial Regulation
2 sources
Get alerts when regulations change
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.